Blogs - Drug Development & Research | Danaher Life Sciences

Danaher
September 17, 20265 min read
A Practical Approach to Automating Oncology NGS Research
Read Article →
Danaher
September 17, 20265 min read
Four Questions to Assess Gaps in Your Biomarker Workflow
Read Article →
Danaher
September 17, 20265 min read
How to Improve Confidence in Low-Abundance Metabolite Detection
Read Article →
Danaher
September 17, 20265 min read
Metabolite Identification by LC-MS: What Users are Asking
Read Article →
Danaher
September 17, 20265 min read
How to Characterize Oligonucleotide Biotransformation with LC–MS
Read Article →
Danaher
September 17, 20265 min read
Six Steps to Strengthen Metabolite Identification and Decision-Ready Measurement
Read Article →
Danaher
August 28, 20263 min read
The Biomarker Bottleneck Has Shifted: Why Connected Workflows Matter
Read Article →
Danaher
August 28, 20263 min read
Enabling Translation-Ready Biomarkers with Connected Workflows
Read Article →
Danaher
August 28, 20263 min read
How automation helps protect data quality across expanding studies
Read Article →
Danaher
August 28, 20263 min read
From Multimodal Data to Decision-Ready Biomarker Insights
Read Article →
Danaher
August 28, 20265 min read
Streamlining Fusion Detection in Translational Oncology with NGS
Read Article →
Danaher
August 28, 20263 min read
Connecting Molecular, Spatial and Functional Biology
Read Article →
Danaher
August 28, 20263 min read
Reproducible Biomarker Data Starts with Standardized Sample Preparation
Read Article →
Danaher
July 31, 20263 min read
5 Biomarker Data Challenges Slowing Discovery and Validation
Read Article →
Danaher
July 16, 20263 min read
How multi omics, automation and AI are transforming biomarker development
Read Article →
Danaher
July 16, 20263 min read
From Discovery to Translational-Ready Biomarker Programs: What Users Are Asking
Read Article →
Danaher
July 01, 20263 min read
Engineering an mRNA Prime Editing platform with broad utility in genome editing
Read Article →
Danaher
June 24, 20263 min read
From Custom CRISPR to Clinical Scale: Rethinking Genomic Medicine Manufacturing
Read Article →

Blog

A Practical Approach to Automating Oncology NGS Research

Four Questions to Assess Gaps in Your Biomarker Workflow

How to Improve Confidence in Low-Abundance Metabolite Detection

Metabolite Identification by LC-MS: What Users are Asking

How to Characterize Oligonucleotide Biotransformation with LC–MS

Six Steps to Strengthen Metabolite Identification and Decision-Ready Measurement

The Biomarker Bottleneck Has Shifted: Why Connected Workflows Matter

Enabling Translation-Ready Biomarkers with Connected Workflows

How automation helps protect data quality across expanding studies

From Multimodal Data to Decision-Ready Biomarker Insights

Streamlining Fusion Detection in Translational Oncology with NGS

Connecting Molecular, Spatial and Functional Biology

Reproducible Biomarker Data Starts with Standardized Sample Preparation

5 Biomarker Data Challenges Slowing Discovery and Validation

How multi omics, automation and AI are transforming biomarker development

From Discovery to Translational-Ready Biomarker Programs: What Users Are Asking

Engineering an mRNA Prime Editing platform with broad utility in genome editing

From Custom CRISPR to Clinical Scale: Rethinking Genomic Medicine Manufacturing